IN THE CLAIMS:

1. (Previously Presented): A method for the treatment of cell proliferative disorders associated with an altered cell dependent kinase activity, comprising:

administering to a mammal in need thereof an effective amount of a compound represented by formula (I):



(I)

wherein

R is a C_3-C_6 cycloalkyl group, which is optionally substituted with a straight or branched C_1-C_6 alkyl group, or is a C_1-C_6 alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_1 is $-(CH_2)_n-R_3$;

n is 0 or an integer from 1 to 4;

R_3 is hydrogen, hydroxy, amino, or a group selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_2 is hydrogen, or

R_2 and R_1, together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

or a pharmaceutically acceptable salt thereof;

provided that when n is 0 and R_2 is hydrogen, R is a C_3-C_6 cycloalkyl group optionally substituted with a straight or branched C_1-C_6 alkyl group.

2. (Currently Amended): The method of Claim 1, wherein the cell proliferative disorder is ~~selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders~~ cancer.

3. (Original): The method of Claim 2, wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, and Kaposi's sarcoma.

4. (Cancelled).

5. (Original): The method of Claim 1, which provides tumor angiogenesis and metastasis inhibition.

6. (Original): The method of Claim 1, which provides cell cycle inhibition or cdk/cyclin dependent inhibition.

7. (Original): The method of Claim 1, further comprising subjecting the mammal in need thereof with a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

8. (Original): The method of Claim 1, wherein R is C_3-C_6 cycloalkyl optionally substituted with a straight or branched C_1 -C_6 alkyl group.

9. (Original): The method of Claim 1, wherein

R is a C_3-C_6 cycloalkyl or an optionally substituted straight or branched C_1-C_4 alkyl group, a cycloalkyl group, an aryl group or an arylalkyl group;

R_1 is a C_1-C_4 alkyl group or a phenyl, phenylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl group, which is optionally substituted as defined in Claim [];

or a pharmaceutically acceptable salt thereof.

10. (Original): The method of Claim 1, wherein

R is a C_3-C_6 cycloalkyl;

R_1 is a C_1-C_4 alkyl group substituted by hydroxy or amino, or is an aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl or heterocyclyl moiety is selected from the group consisting of phenyl or optionally benzocondensed pyiridine, indole, thiophene, thiazole, isoxazole, furane, piperidine, morpholine, each optionally further substituted;

or a pharmaceutically acceptable salt thereof.

11. (Original): The method of Claim 1, wherein R_1 and R_2, together with the nitrogen atom to which they are bonded, form an optionally substituted heterocyclyl ring.

12. (Original): The method of Claim 11, wherein the heterocyclyl ring is piperidino, piperazino or morpholino.

13. (Original): The method of Claim 7, wherein the compound is selected from the group consisting of

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-piperidinyl)ethyl]urea;

4-[({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)methyl]benzenesulfonamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2-pyridinyl)ethyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-pyrrolidinyl)ethyl]urea;

N-(3-chlorophenethyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethoxybenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-chlorobenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(4-piperidinylmethyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(3-fluorobenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(3,4-dimethoxybenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(4-chlorobenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(3,4-dihydroxybenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(3,4-dimethylbenzyl)urea;

N-[3-(tert-butyl)-1H-pyrazol-5-yl)]-N'-(3-chlorophenethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-piperidinylmethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-fluorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxybenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethylbenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxy-1-methyl-2-phenylethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[(l-ethyl-2-pyrrolidinyl)methyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2H-imidazol-4-yl)ethyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(5-methoxy-lH-indol-3-yl)ethyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzodioxol-5-ylmethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-(4-morpholinyl)ethyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dichlorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-ethoxybenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dichlorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxybenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-fluorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-trifluoromethylbenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-methylbenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;

N-cyclobutyl-N'-(3-cyclopenthyl-1H-pyrazol-5-yl)urea;

N-(3-cyclopenthyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;

4-(1,3-benzodioxol-5-ylmethyl)-N-(3-cyclopenthyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(1-benzyl-4-piperidinyl)urea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-benzylurea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-phenethylurea:

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-propylurea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;

N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;

4-(1,3-benzodioxol-5-yl-methyl)-N-(3-phenethyl-1H-pyrazol5-yl)-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-benzylurea;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-phenethylurea;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-propylurea;

N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-butylurea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dimethylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxy-4-chlorophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,5-dimethylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxamidophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N,-(3-carboxy-4-hydroxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,6-dimethylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-cyanophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-acetylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-benzimidazol-6yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxy-3-methoxybenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-benzylurea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-{3-[3-(dimethylamino)-1-propynyl]phenyl}urea;

N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]methanesulfonamide;

2-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)anilino]acetamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N,-[3-(3-hydroxy-1-butynyl)phenyl]urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-5-yl)urea;

4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)benzenesulfonamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxyphenyl)urea;

N-(3-cyclopropyl-lH-pyrazol-5-yl)-N'-phenylurea;

N-[4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]-N-methylacetamide;

N-(2-{[cyclohexyl(methyl)amino]methyl}phenyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-methoxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-ethynylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-aminophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxy-4-methylphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-3-oxo-3,4-dihydro-1(2H)-quinoxalinecarboxamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-pyridinylmethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-furylmethyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzothiazol-5yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea;

N-[5-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-2-

methoxyphenyl]acetamide;

N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-4-methoxyphenyl]acetamide;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-aminophenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-imidazol-6yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxyphenyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenyl)urea, and

pharmaceutically acceptable salts thereof.

14. (Original): The method of Claim 1, wherein the mammal is a human.

15. – 20. (Cancelled).

21. (Currently Amended): A process for preparing a compound represented by formula I



(I)

or a pharmaceutically acceptable salt thereof

---

wherein

R is a C_3-C_6 cycloalkyl group, which is optionally substituted with a straight or branched C_1-C_6 alkyl group, or is a C_1-C_6 alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino,

aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_1 is $-(CH_2)_n-R_3$;

n is 0 or an integer from 1 to 4;

R_3 is hydrogen, hydroxy, amino, or a group selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_2 is hydrogen, or

R_2 and R_1, together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl,

cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

or a pharmaceutically acceptable salt thereof;

provided that when n is 0 and R_2 is hydrogen, R is a C_3-C_6 cycloalkyl group optionally substituted with a straight or branched C_1-C_6 alkyl group ~~the 3-ureido-pyrazole derivative of Claim 15, or a pharmaceutically acceptable salt thereof~~, comprising:

(a) reacting a compound represented by formula (II):



(II)

with a compound represented by formula (III):

R_1-NCO (III)

wherein R and R_1 are as defined in Claim 15,



(IV)

to produce a compound represented by formula (IV):

wherein R and R_1 are as defined above ~~in Claim 15~~; and

(b) selectively hydrolizing a compound represented by formula (IV) in a basic medium to produce a compound represented by formula (I).

22. (Currently Amended): A process for preparing a compound represented by formula I



(I)

or a pharmaceutically acceptable salt thereof

---

wherein

R is a C_3-C_6 cycloalkyl group, which is optionally substituted with a straight or branched C_1-C_6 alkyl group, or is a C_1-C_6 alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_1 is $-(CH_2)_n-R_3$;

n is 0 or an integer from 1 to 4;

R_3 is hydrogen, hydroxy, amino, or a group selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

R_2 is hydrogen, or

R_2 and R_1, together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkynyl, C_2-C_4 aminoalkynyl or C_2-C_4 hydroxyalkynyl substituents;

or a pharmaceutically acceptable salt thereof;

provided that when n is 0 and R_2 is hydrogen, R is a C_3-C_6 cycloalkyl group optionally substituted with a straight or branched C_1-C_6 alkyl group.

~~the 3-ureido-pyrazole derivative of Claim 15, or a pharmaceutically acceptable salt thereof,~~

comprising:

(c) reacting a compound represented by formula (V):



wherein R has the meanings given above ~~is defined in Claim 15~~,

with 4-nitrophenyl chloroformate, or a polymer supported form of 4-nitrophenyl chloroformate, to produce a compound represented by formula (VI), or a polymer supported form of the compound represented by formula (VI):



(VI)

wherein R has the meanings given above ~~is defined in Claim 15~~;

(d) reacting a compound represented by formula (VI) with a compound represented by formula (VII):

R_1R_2NH (VII)

wherein R_1 and R_2 are as defined above ~~in Claim 15~~,

to produce a compound represented by formula (VIII):



wherein R, R_1 and R_2 are as defined above ~~in Claim 15~~;

(e) hydrolizing a compound represented by formula (VIII) in acidic medium to produce a compound represented by formula (I); and, optionally, converting the 3-ureido-pyrazole derivative represented by formula (I) into another derivative represented by formula (I), and/or into a salt thereof.

23. (Cancelled).